Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.70 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.70 |
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.68 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.68 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
| ▸ | HINT1 | P49773 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 4/20 | 0.58 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.57 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25391360 | 1.00 | TAS1R3 (0.70) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL14576179 | 1.00 | TAS1R3 (0.70) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL600378 | 1.00 | TAS1R3 (0.70) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL26067681 | 1.00 | TAS1R3 (0.70) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL26067564 | 0.94 | NT5E (0.67) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL26067581 | 0.94 | NT5E (0.67) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL21715304 | 0.93 | TGM2 (0.69) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL21715305 | 0.93 | TGM2 (0.69) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL26067682 | 0.93 | TGM2 (0.69) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL843561 | 0.93 | TAS1R3 (0.68) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2385951-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254856-A1 | MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL | LG ELECTRONICS INC. (KR) | 2011-10-20 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | TAS1R3 4121/4885TAS1R1 3875/4885NT5E 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.